Avonex Syringe Component Approval Is "Good News" Despite Charge, Biogen Idec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's approval in March of a new component for the pre-filled syringe is "good news" for the MS therapy but resulted in a first quarter charge of $11 mil. for finished product that is no longer needed, the company says. Avonex sales grew 5.4% during the quarter, driven by international gains.
You may also be interested in...
Biogen Idec Expects Tysabri-Related Charges Up To $100 Mil. In 2005
First quarter charges related to the withdrawn multiple sclerosis therapy totaled $36 mil. Inventory charges are expected in the second quarter as the company completes the natalizumab production cycle; idle capacity charges totaling $20 mil.-$30 mil. are likely in the latter half of the year.
Biogen Idec Expects Tysabri-Related Charges Up To $100 Mil. In 2005
First quarter charges related to the withdrawn multiple sclerosis therapy totaled $36 mil. Inventory charges are expected in the second quarter as the company completes the natalizumab production cycle; idle capacity charges totaling $20 mil.-$30 mil. are likely in the latter half of the year.
Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal
Rebif is the leader in new prescription growth with a 22.4% share, an all-time high, at the end of March, Serono says. The company is focusing marketing of Rebif on efficacy, a message to which Tysabri helped draw attention. Serono expects Rebif to emerge as the global MS leader by 2006.